trending Market Intelligence /marketintelligence/en/news-insights/trending/j4yjqswa5_vxkuqtfixuda2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Patent and Trademark Office OKs MediWound patent for connective tissue disease

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Patent and Trademark Office OKs MediWound patent for connective tissue disease

The U.S. Patent and Trademark Office granted a patent for MediWound Ltd.'s proprietary injectable bromelain solution, MWPC003, for the treatment of connective tissue diseases.

MWPC003 is an investigational sterile injectable solution containing a mixture of the same pharmaceutical-grade proteolytic enzymes used in the company's burn debridement treatment, Nexobrid, which is approved in Europe and other locations.

The patent provides protection for the drug in the treatment of a variety of connective tissue diseases, such as Dupuytren's contracture, Peyronie's disease and scar treatment, among others.